Catherine M. Bollard, M.D.
Department of Pediatrics
Section of Hematology-Oncology
Department of Immunology
Department of Medicine
Baylor College of Medicine
Pediatric Lymphoma Program
- M.B.Ch.B., Otago University School of Medicine, Dunedin, New Zealand
- Residency, Pediatrics, Auckland Children's Hospital, Auckland, New Zealand
- Residency, Internal Medicine, Auckland Children's Hospital, Auckland, New Zealand
- Residency, Pediatric Hematology and Oncology, St. Bartholomew's Hospital, London, England
- Fellowship, Pediatric Hematology and Oncology, Auckland Children's Hospital, Auckland, New Zealand
- Fellowship, Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX
- Royal Australasian College of Physicians (Pediatrics)
- Royal College of Pathologists of Australasia (Hematology)
- American Society of Blood and Marrow Transplantation
- American Society of Gene Therapy
- American Society of Hematology
- Hematology Society of Australia and New Zealand
- Hodgkin Disease Committee, Children's Oncology Group
- Inspector, Foundation for the Accreditation of Cellular Therapy
- International Society of Cellular Therapy
- Biology of Blood and Marrow Transplant
- Bone Marrow Transplantation
Clinical Special Interests
- Bone Marrow Transplantation
- Cell and Gene Therapy
Dr. Bollard's research interests involve using cytotoxic T cells (CTL) for viral and malignant diseases. Dr Bollard is a principal investigator on two clinical trials assessing the safety of adoptively transferred donor-derived virus-specific CTL for the prophylaxis and treatment of CMV and adenoviral infection post allogeneic stem cell transplant. She is also evaluating the efficacy of tumor-specific CTL in patients with relapsed EBV positive Hodgkin's disease and non-Hodgkin Lymphoma. Further, she is developing gene therapy strategies to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols. Specifically, she demonstrated a method of genetically modifying CTL to improve their potential as cell therapy for Hodgkin Disease. The use of CTL expressing a dominant negative TGF beta receptor mutant is likely to improve cell therapy for patients with not only Lymphoma, but also other cancers that use TGF beta secretion as a means to evade the immune response.
- Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun;39(11):677-86.
- Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec;12(12):1277-84.
- Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun;29(3):250-60.
- Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct;12(10):1160-6.
- Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec;36(11):1001-8.
- Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 1;105(5):1898-904.
- Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15;175(6):4137-47. Erratum in: J Immunol. 2005 Nov 1;175(9):6238.
- Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20;200(12):1623-33.
- Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15;102(6):2292-9. Erratum in: Blood. 2004 Sep 15;104(6):1605.
- Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug;27(4):317-27.
- Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 1;99(9):3179-87.
- Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15;99(6):2009-16.